Baird Riterates a 'Neutral' on Regeneron Pharma (REGN); Q311 Uneventful; Still Think Best Case Scenario Is Priced In

Baird reiterates a 'Neutral' on Regeneron Pharma (NASDAQ: REGN) price target of $56.00.

Baird analyst says, "Remain Neutral-rated after an uneventful Q311 report. The story here remains primarily around the commercial uptake of Eylea with approval expected next month. Given that we think we have already modeled in a best-case scenario for Eylea and indeed for other agents Zaltrap and Arcalyst, we think the stock is fully valued here. Add in the ongoing Genentech IP litigation, and we like our current position on the sidelines."

For more ratings news on Regeneron Pharma click here and for the rating history of Regeneron Pharma click here.

Shares of Regeneron Pharma closed at $55.30 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Regeneron Pharma (REGN) PT Raised to $756 at Bernstein SocGen Group
• New Street Research Upgrades Micron Technology (MU) to Buy
• Freedom Broker Upgrades Lifeway Foods (LWAY) to Buy